Corporate ➞ Investor Relations

NOTICE: On March 12, 2020, the SEC issued a Final Rule No. 34-88365 that amends the eligibility criteria for non-accelerated filer status to include issuers that qualify as smaller reporting companies (SRCs) with annual revenues of less than $100 million and public float of less than $700 million. Utah Medical Products, Inc. now qualifies as a non-accelerated filer. As a result, UTMD's 2023 SEC Form 10-K will be filed on or before April 1, 2024 (90 days from year-end) and 2024 SEC Form 10-Q Quarterly Reports will be filed on or before 45 days from each quarter-end.

UTMD is dedicated to a sustained substantial increase in shareholder value by focusing financially on earnings per share growth and a high return on shareholder equity; and by focusing functionally on developing, manufacturing and marketing specialty medical devices that provide a real improvement in quality, safety and overall cost of care.

Information provided here is intended to help you better understand UTMD, so you can make an investment decision consistent with your own preferences and risk aversion.

CORPORATE STOCK INFORMATION

Utah Medical Product's common stock trades on the NASDAQ Global Market (symbol: UTMD). Use the links below to access stock information.

• UTMD Overview Stock Report
• Advanced Stock Charting
• Real-Time Quotes
• Historical Data
• Revenue/EPS Summary
• Dividend History